Neonc Technologies Holdings, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Amir Farrokh Heshmatpour
- Full Time Employees
- 5
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 23975 Park Sorrento Calabasas CA United States of America 90069
- IPO Date
- Mar 26, 2025
- CIK
- 0001979414
- Website
- neonctech.com
- Similar Companies
- Business
- NEONC Technologies Holdings, Inc. (NTHI) is a clinical-stage biopharmaceutical company that develops proprietary, patented platform technologies to transport therapeutics across the blood-brain barrier for treating brain cancers and central nervous system (CNS) diseases; its lead candidates include NEO100, a purified perillyl alcohol formulation in Phase IIa clinical trials for recurrent glioblastoma with FDA Orphan Drug and Fast Track designations, NEO212, a conjugate of temozolomide and perillyl alcohol in Phase I/II trials for primary and secondary brain tumors via oral administration, and the broader NEO platform supporting intranasal and transfemoral delivery methods for enhanced therapeutic efficacy in CNS malignancies such as grade 4 astrocytoma. The company targets oncology biopharmaceutical markets, focusing on glioblastoma and other intracranial tumors, with operations centered in the United States and plans for expansion into the MENA region. Founded in 2008 and headquartered in Calabasas, California, NEONC holds exclusive worldwide rights from USC to an intellectual property portfolio of 135 U.S. and international patents issued and pending, extending protections to 2038. Recent developments include the completion of an $18.5 million financing round in 2024 that valued the company post-money at approximately $220 million and advanced Phase II trials under FDA Fast Track status; a strategic acquisition of advanced AI and 3D bioprinting intellectual property; the appointment of Ishwar Puri to its Board of Directors; initiation of Cohort 3 enrollment in the Phase 1 trial of NEO212; board approval in June 2025 for a $50 million equity investment and MENA expansion via non-binding term sheet with Quazar Investment, including 1.4 million shares at $25 per share and a sub-license agreement with NuroCure; and receipt of the Breakthrough Medical Technology Achievement Award from the California Investment Forum.
NeOnc Receives FDA Written Feedback on NEO212 CMC Development and Capsule-to-Tablet Transition
Wall Street is Watching These Biotechs
NeOnc Ignites Explosive Summer: 4 New Research Reports + UAE/Dubai Drug Approval Fuel Breakout Momentum
NeOnc Technologies Receives UAE IND Approval for NEO100, Expanding Global Development Ahead of Anticipated Phase 2 Data Milestone
WSTPR Catalyst Watch: Abu Dhabi Regulatory Clearance Adds Momentum to NeOnc's Global Neuro-Oncology Strategy
NeOnc's Global Expansion Accelerates After Abu Dhabi IND Approval for NEO212
Brain Cancer Innovator NeOnc Heads into Critical Data Season with Fresh Abu Dhabi IND
NeOnc Technologies Secures UAE IND Approval for NEO212 Following Successful Phase 1 Completion, Advancing Toward Global Phase 2 Development
WSTPR Catalyst Watch: NeOnc Strengthens Capital Position Ahead of Potentially Transformational Neuro-Oncology Updates
The Race to Defeat Brain Cancer Could Become One of the Biggest Biotech Stories of the Decade
The Next Great AI Revolution May Be Drug Delivery
The Next Great AI Revolution May Be Drug Delivery
NeOnc Technologies Gains Growing Institutional Support Ahead of Key Brain Cancer Clinical Milestones
NeOnc Provides Business Update and Reports Q1 2026 Financial Results
Forget the 242% Biotech Meme. This Brain Cancer Stock Has a $38 Analyst Target and Trades at $6
Biotech's Next Wave May Already be in Motion
Where Executives Are Doubling Down on Their Companies’ Fortunes
Where Executives Are Doubling Down on Their Companies' Fortunes
NeOnc CEO Accelerates Insider Buying with $500K+ Investment Ahead of Imminent NEO100 Phase 2a Data Catalysts
Neonc Technologies (NASDAQ:NTHI) President Amir Heshmatpour Buys 5,000 Shares